Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: An analysis of the EUROPA study including 1251 Polish patients

PharmacoEconomics

Volumn 26, Issue 10, 2008, Pages 861-877

  Redekop, W Ken ^a   Orlewska, Ewa ^b   Maciejewski, Pawel ^c   Rutten, Frans F H ^a   Niessen, Louis W ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Centre for Pharmacoeconomics   (Poland)

^c GROCHOWSKI HOSPITAL   (Poland)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coronary artery disease, treatment; Cost effectiveness; Perindopril, therapeutic use

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; NITRIC ACID DERIVATIVE; PERINDOPRIL; VASODILATOR AGENT;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLAND; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MONTE CARLO METHOD; PERINDOPRIL; POLAND; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK; SECONDARY PREVENTION;

EID: 52149120923     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826100-00006     Document Type: Article

References (29)

1. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994 Oct; 90 (4): 1731-8
2. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992 Nov 14; 340 (8829): 1173-8
3. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Feb 20; 342 (3): 145-53
4. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep 6; 362 (9386): 782-8
5. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hill, 1993
6. Cook JR, Drummond M, Glick H, et al. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med 2003 Jun 30; 22 (12): 1955-76
7. Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005 Mar; 149 (3): 434-43
8. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994 Sep-Oct; 3 (5): 309-19
9. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998 Dec; 7 (8): 723-40
10. ESC/ACC Committee. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000 Sep; 21 (18): 1502-13
11. Orlewska E, Cel M. Standard list of inpatient costs [in Polish]. Farmakoekonomika 2003; 6 (2): 1-22
12. National Health Fund Management Resolution 164/2004 of 01/ 07/2004 on setting the catalog of inpatient medical services (appendix 1) [in Polish]. Warsaw: National Health Fund (Poland), 2004
13. Eurostat. Harmonized Indices Of Consumer Prices (HICPs). All items: index [online]. Available from URL: http://epp.eurostat.ec.europa.eu/portal/page?
14. Data on file, IMS Poland National Data 2004 (IMS data view).
15. Prosper pharmaceutical wholesale pricelist 2004 [in Polish]. Warsaw: Prosper, 2004
16. Polish register of reimbursed pharmaceuticals II 2004 [in Polish]. Piotrków Trybunalski: Wydawnictwo JWC, 2004
17. Orlewska E, Mierzejewski P. Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines. Eur J Health Econ 2003 Nov; 4 (4): 296-303
18. Orlewska E, Mierzejewski P. Project of Polish guidelines for costing: methods and standard costs for pharmacoeconomic evaluations [in Polish]. Farmacoeconomika 2003; 1: 2-8
19. Brouwer WB, Niessen LW, Postma MJ, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005 Aug 20; 331 (7514): 446-8
20. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press, 1996
21. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 May; 17 (5): 479-500
22. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence, 2004 Apr
23. Orlewska E. The cost-effectiveness of Arthrotec 75 versus diclofenac SR 75 in the treatment of rheumatoid arthritis and osteoarthritis in Poland [in Polish]. Farmakoekonomika 2000; 1: 2-18
24. World health report 2002. Geneva: World Health Organization, 2002
25. Macroeconomics and health: investing in health for economic development: report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001
26. The world health report 2002: Reducing risks, promoting healthy life. Geneva, World Health Organization [online]. Available from URL: http://www.who.int/whr/2002/en/ [Accessed 2008 Jun 23]
27. Briggs A, Mihaylova B, Sculpher M, et al. The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA Study. Heart 2007 Sep; 93 (9): 1081-6
28. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
29. Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003 Feb 25; 107 (7): 960-5